Epidemiology and risk factors: An update

Textbook of Breast Cancer: A Clinical Guide to Therapy

Volumn , Issue , 2006, Pages 1-15

  Setiawan, Veronica W ^a   Feigelson, Heather S ^b   Henderson, Brian E ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b AMERICAN CANCER SOCIETY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954540424     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (67)

1. Parkin DM, The global burden of cancer. Semin Cancer Biol 1998; 8: 219-35.
2. Lacey JV Jr, Devesa SS, Brinton LA, Recent trends in breast cancer incidence and mortality. Environ Mol Mutagen 2002; 39: 82-8.
3. Pisani P, Parkin DM, Bray F et al, Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999; 83: 18-29.
4. Feigelson HS, Breast cancer: epidemiology and molecular endocrinology. In: Hormones, Genes, and Cancer, 1st edn (Henderson BE, Ponder B, Ross RK, eds). New York: Oxford University Press, 2003: 120-38.
5. Pike MC, Kolonel LN, Henderson BE et al, Breast cancer in a multiethnic cohort in Hawaii and Los Angeles: risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in whites. Cancer Epidemiol Biomarkers Prev 2002; 11: 795-800.
6. Pike MC, Krailo MD, Henderson BE et al, 'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature 1983; 303: 767-70.
7. Henderson BE, Feigelson HS, Hormonal carcino-genesis. Carcinogenesis 2000; 21: 427-33.
8. Travis RC, Key TJ, Oestrogen exposure and breast cancer risk. Breast Cancer Res 2003; 5: 239-47.
9. The Endogenous Hormones and Breast Cancer Collaborative Group, Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002; 94: 606-16.
10. Shimizu H, Ross RK, Bernstein L et al, Serum oestrogen levels in postmenopausal women: comparison of American whites and Japanese in Japan. Br J Cancer 1990; 62(3): 451-3.
11. Probst-Hensch NM, Pike MC, McKean-Cowdin R et al, Ethnic differences in post-menopausal plasma oestrogen levels: high oestrone levels in Japanese-American women despite low weight. Br J Cancer 2000; 82: 1867-70.
12. Pike MC, Spicer DV, Dahmoush L et al, Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993; 15: 17-35.
13. Collaborative Group on Hormonal Factors in Breast Cancer, Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047-59.
14. Ross RK, Paganini-Hill A, Wan PC et al, Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000; 92: 328-32.
15. Schairer C, Lubin J, Troisi R et al, Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283: 485-91.
16. Henderson BE, Ross R, Bernstein L, Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 1988; 48: 246-53.
17. Brinton LA, Schairer C, Hoover RN et al, Menstrual factors and risk of breast cancer. Cancer Invest 1988; 6: 245-54.
18. Titus-Ernstoff L, Longnecker MP, Newcomb PA et al, Menstrual factors in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998; 7: 783-9.
19. The Collaborative Group on Hormonal Factors in Breast Cancer, Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. Lancet 2002; 360: 187-95.
20. MacMahon B, Cole P, Lin TM et al, Age at first birth and breast cancer risk. Bull World Health Organ 1970; 43: 209-21.
21. Yuan JM, Yu MC, Ross RK et al, Risk factors for breast cancer in Chinese women in Shanghai. Cancer Res 1988; 48: 1949-53.
22. Lee SY, Kim MT, Kim SW et al, Effect of lifetime lactation on breast cancer risk: a Korean women's cohort study. Int J Cancer 2003; 105: 390-3.
23. National Cancer Institute. Abortion, Miscarriage, and Breast Cancer Risk. Available at http://cis.nci.nih.gov/fact/3_75.htm.
24. van den Brandt PA, Spiegelman D, Yaun SS et al, Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 2000; 152: 514-27.
25. Potischman N, Swanson CA, Siiteri P et al, Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst 1996; 88: 756-8.
26. The Endogenous Hormones and Breast Cancer Collaborative Group, Body mass index, serum sex hormones, and breast cancer risk in post-menopausal women. J Natl Cancer Inst 2003; 95: 1218-26.
27. Connolly BS, Barnett C, Vogt KN et al, A meta-analysis of published literature on waist-to-hip ratio and risk of breast cancer. Nutr Cancer 2002; 44: 127-38.
28. Feigelson HS, Jonas CR, Teras LR et al, Weight gain, body mass index, hormone replacement therapy and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev 2004; 13: 220-4.
29. Friedenreich C, Bryant HE, Courneya KS, Case-control study of lifetime physical activity and breast cancer risk. Am J Epidemiol 2001; 154: 336-47.
30. Bernstein L, Henderson BE, Hanisch R et al, Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst 1994; 86: 1403-8.
31. Ellison RC, Zhang Y, McLennan CE et al, Exploring the relation of alcohol consumption to risk of breast cancer. Am J Epidemiol 2001; 154: 740-7.
32. Smith-Warner SA, Spiegelman D, Yaun SS et al, Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA 1998; 279: 535-40.
33. Dorgan JF, Baer DJ, Albert PS et al, Serum hormones and the alcohol-breast cancer association in postmenopausal women. J Natl Cancer Inst 2001; 93: 710-15.
34. The Collaborative Group on Hormonal Factors in Breast Cancer, Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-27.
35. Colditz GA, Rosner B, Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol 2000; 152: 950-64.
36. Olsson HL, Ingvar C, Bladstrom A, Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. Cancer 2003; 97: 1387-92.
37. The Million Women Study Collaborators, Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-27.
38. Viscoli CM, Brass LM, Kernan WN et al, A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001; 345: 1243-9.
39. Hulley S, Furberg C, Barrett-Connor E et al, Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/ Progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 58-66.
40. Writing Group for the Women's Health Initiative Investigators, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
41. Beral V, Banks E, Reeves G, Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002; 360: 942-4.
42. American Cancer Society. Breast cancer facts and figures 2003-2004. Available at http://www.cancer.org.
43. The U.S. Preventive Services Task Force. Chemo-prevention: Hormonal Replacement Therapy. Available at http://www.ahcpr.gov/clinic/uspstf/uspspmho.htm.
44. Pharoah PD, Day NE, Duffy S et al, Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 1997; 71: 800-9.
45. Ford D, Easton DF, Peto J, Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995; 57: 1457-62.
46. Welcsh PL, King MC, BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 2001; 10: 705-13.
47. Ellisen LW, Haber DA, Hereditary breast cancer. Annu Rev Med 1998; 49: 425-36.
48. Sellers TA, Genetic factors in the pathogenesis of breast cancer: their role and relative importance. J Nutr 1997; 127(5 Suppl): 929-32S.
49. Chenevix-Trench G, Spurdle AB, Gatei M et al, Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst 2002; 94: 205-15.
50. Bretsky P, Haiman CA, Gilad S et al, The relationship between twenty missense ATM variants and breast cancer risk: the Multiethnic Cohort. Cancer Epidemiol Biomarkers Prev 2003; 12: 733-8.
51. CHEK2-Breast Cancer Consortium, Low-pene-trance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002; 31: 55-9.
52. Feigelson HS, Ross RK, Yu MC et al, Genetic susceptibility to cancer from exogenous and endogenous exposures. J Cell Biochem Suppl 1996; 25: 15-22.
53. Thompson PA, Ambrosone C, Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. J Natl Cancer Inst Monogr 2000; 27: 125-34.
54. Feigelson HS, McKean-Cowdin R, Coetzee GA et al, Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res 2001; 61: 785-9.
55. Wu AH, Seow A, Arakawa K et al, HSD17B1 and CYP17 polymorphisms and breast cancer risk among Chinese women in Singapore. Int J Cancer 2003; 104: 450-7.
56. Hirschhorn JN, Altshuler D, Once and again-issues surrounding replication in genetic association studies. J Clin Endocrinol Metab 2002; 87: 4438-41.
57. Haiman CA, Stram DO, Pike MC et al, A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort. Hum Mol Genet 2003; 12: 2679-92.
58. Land CE, Studies of cancer and radiation dose among atomic bomb survivors. The example of breast cancer. JAMA 1995; 274: 402-7.
59. Carmichael A, Sami AS, Dixon JM, Breast cancer risk among the survivors of atomic bomb and patients exposed to therapeutic ionising radiation. Eur J Surg Oncol 2003; 29: 475-9.
60. Schnitt SJ, Benign breast disease and breast cancer risk: morphology and beyond. Am J Surg Pathol 2003; 27: 836-41.
61. Ursin G, Ma H, Wu AH et al, Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev 2003; 12: 332-8.
62. Prentice RL, Future possibilities in the prevention of breast cancer: fat and fiber and breast cancer research. Breast Cancer Res 2000; 2: 268-76.
63. Bingham SA, Luben R, Welch A et al, Are imprecise methods obscuring a relation between fat and breast cancer? Lancet 2003; 362: 212-14.
64. Hunter DJ, Spiegelman D, Adami HO et al, Cohort studies of fat intake and the risk of breast cancer-a pooled analysis. N Engl J Med 1996; 334: 356-61.
65. Goldin BR, Adlercreutz H, Gorbach SL et al, Estrogen excretion patterns and plasma levels in vegetarian and omnivorous women. N Engl J Med 1982; 307: 1542-7.
66. Willett WC, Hunter DJ, Stampfer MJ et al, Dietary fat and fiber in relation to risk of breast cancer. An 8-year follow-up. JAMA 1992; 268: 2037-44.
67. Peeters PH, Keinan-Boker L, van der Schouw YT et al, Phytoestrogens and breast cancer risk. Review of the epidemiological evidence. Breast Cancer Res Treat 2003; 77: 171-83.